World Kidney Day: Top 7 Breakthroughs in Kidney Disease Treatment

Kidney disease treatment is changing rapidly. New drug indications are expanding options for patients with chronic kidney disease, while xenotransplantation, gene therapy, and new approaches to kidney transplantation are moving from experimental concepts toward clinical reality.

Chronic kidney disease (CKD) is an escalating global health challenge, impacting over 35 million individuals in the United States and an estimated 100 million across Europe. Despite its widespread prevalence, CKD remains underdiagnosed until its advanced stages, leading to severe complications, including kidney failure, cardiovascular disease, and increased mortality.

Since this article was first published in 2025, several of these fields have continued to evolve. Here are seven breakthroughs shaping kidney disease treatment in 2026, what the evidence currently shows, and what they could mean for patients and future clinical research.

Pig Kidney Transplantation Successfully Bridges a Patient to a Human Kidney

In a major milestone for xenotransplantation, a genetically modified pig kidney supported a patient with end-stage kidney disease for 271 days without dialysis before he later successfully received a human donor kidney.

The patient received the gene-edited pig kidney in January 2025. After approximately six months of stable function, progressive microvascular injury eventually led to graft failure. The xenograft was removed, and 82 days later, the patient received a human donor kidney with immediate graft function.

Key Clinical Findings:

• The pig kidney maintained dialysis independence for 271 days, the longest reported period in a living recipient.
• No transmission of porcine pathogens was detected.
• The subsequent human kidney transplant showed immediate graft function.
• Researchers found no evidence of clinically significant sensitization caused by the previous xenotransplant.

Why It Matters for Kidney Patients:

• Provides evidence that pig kidneys could potentially serve as a bridge to human transplantation.
• Suggests xenotransplantation may not prevent a later successful human kidney transplant.
• Could eventually help address donor kidney shortages and reduce time spent on dialysis.

Primary source: The Lancet, “Porcine kidney xenotransplantation as a bridge to allotransplantation: a first-in-human study,” 2026.

FDA Approval of Ozempic for Chronic Kidney Disease (CKD) Progression

On January 28, 2025, the FDA granted approval for Ozempic (semaglutide) as the first GLP-1 receptor agonist indicated for reducing the risk of kidney disease progression, kidney failure, and cardiovascular mortality in patients with type 2 diabetes and CKD.

Key Clinical Findings (FLOW Phase 3b Trial):

• 24% reduction in kidney disease progression, kidney failure, and cardiovascular death vs. placebo.
• Trial was terminated early due to overwhelming efficacy, underscoring its transformative impact on CKD management.
• Expands nephrology treatment options beyond SGLT2 inhibitors and RAAS blockers.

Why It Matters for Kidney Patients:

• Delays CKD progression, potentially preventing the need for dialysis or transplantation.
• Reduces cardiovascular mortality, a major cause of death in CKD patients.
• Enhances therapeutic strategies for the 40% of type 2 diabetes patients who develop CKD.

HIV-Positive Kidney Transplants: A Safe and Effective Option

A landmark study from Johns Hopkins Medicine has provided long-term clinical validation that kidney transplants between HIV-positive donors and recipients are as safe and effective as transplants from HIV-negative donors.

Key Scientific and Policy Implications:

• First large-scale study demonstrating comparable survival and graft success rates between HIV-positive and HIV-negative transplant groups.
• No significant differences in organ rejection, graft failure, or mortality.
• Findings support the expansion of donor eligibility, potentially increasing the available donor pool.
• Results could drive policy changes, increasing organ accessibility for HIV-positive patients with end-stage kidney disease.

Why It Matters for Kidney Patients:

• Expands transplant eligibility for HIV-positive patients.
• Shortens organ wait times, addressing critical shortages.
• Improves long-term survival and quality of life.

Targeted Therapies Transform Treatment for Rare Kidney Diseases

In 2025 and 2026, several targeted therapies reached patients with rare kidney diseases, marking a shift from broad disease management toward treatments designed around specific biological pathways.

In March 2025, the FDA approved Fabhalta (iptacopan) as the first treatment for adults with C3 glomerulopathy (C3G) to reduce proteinuria. In July 2026, the FDA also approved Trutakna (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk for disease progression.

Key Clinical Findings:

• In a pivotal study of 74 adults with C3G, iptacopan produced a 35% reduction in proteinuria relative to placebo at six months.

• Trutakna became the first FDA-approved therapy targeting both BAFF and APRIL, two pathways involved in the production of abnormal IgA.

• In its pivotal trial, patients receiving Trutakna experienced an average 46% reduction in proteinuria from baseline at nine months.

• Trutakna received accelerated approval based on proteinuria reduction; whether it slows long-term kidney function decline remains under investigation.

Why It Matters for Kidney Patients:

• Expands treatment options for rare kidney diseases that historically had limited disease-specific therapies.

• Reflects a broader shift toward precision medicine in nephrology, targeting mechanisms underlying individual kidney diseases.

• Could help slow disease progression as new therapies move beyond broad immunosuppression toward more targeted approaches.

Primary sources: FDA, Fabhalta (iptacopan) approval for C3 glomerulopathy, 2025; FDA, Trutakna (atacicept-vymj) approval for primary IgA nephropathy, 2026.

Awake Kidney Transplantation: Redefining Recovery Standards

On June 24, 2024, Northwestern Medicine performed its first-ever awake kidney transplant, utilizing regional spinal anesthesia instead of general anesthesia. This innovative approach significantly reduced post-surgical risks and accelerated recovery.

Key Clinical Advancements:

• First successful awake kidney transplant.
• Eliminated general anesthesia risks, making transplantation safer for high-risk patients.
• Enabled rapid post-operative mobilization, with the patient discharged in less than 24 hours (vs. the standard 2-3 days).

Why It Matters for Kidney Patients:

• Offers a safer alternative for patients with anesthesia-related complications.
• Accelerates recovery, improving post-operative outcomes.
• Potential to redefine transplant protocols, increasing procedural accessibility.

CAR-T Therapy Could Expand Access to Kidney Transplantation

CAR-T therapy is best known as a treatment for certain blood cancers, but researchers are now exploring whether engineered immune cells could help solve one of the most difficult problems in kidney transplantation.

In 2026, early clinical reports described the use of CD19-directed CAR-T cells in highly HLA-sensitized patients, whose pre-existing antibodies can make finding a compatible donor kidney extremely difficult.

Key Clinical Findings:

• CD19 CAR-T therapy is being investigated as a way to target B-cell populations involved in producing antibodies against potential donor organs.
• An early clinical report described successful kidney transplantation following anti-CD19 CAR-T therapy in a highly HLA-sensitized patient.
• Additional early cases suggest that immune-cell engineering may help some patients overcome barriers that previously prevented transplantation.
• Evidence remains preliminary and is currently based on very small numbers of patients.

Why It Matters for Kidney Patients:

• Could potentially expand transplantation opportunities for highly sensitized patients who struggle to find compatible donors.
• Introduces a completely new strategy for managing transplant-related immune barriers.
• Could reduce dependence on existing desensitization approaches if efficacy and safety are confirmed.
• Larger studies are needed to determine durability, infection risk, immune recovery, and long-term transplant outcomes.

Gene Therapy for Inherited Kidney Disease Moves Into the Clinic

Gene therapy for kidney disease has taken an important step from preclinical research toward human studies. Earlier research identified kidney-targeting vectors such as AAV-KP1, demonstrating the potential to deliver genetic material to renal tissue. In 2026, researchers reported early clinical results from a different gene therapy approach in patients with nephropathic cystinosis, a rare inherited disease caused by mutations in the CTNS gene.

The Phase 1–2 study evaluated CTNS-RD-04, an ex vivo therapy using patients’ own CD34+ hematopoietic stem cells genetically modified to carry functional CTNS DNA.

Key Clinical Findings:

• Six patients, aged 20 to 46, received the investigational gene therapy and were followed for 29 to 63 months.

• All participants achieved sustained hematopoietic reconstitution following treatment.

• White-cell cystine levels decreased from baseline in five of the six patients.

• Most reported adverse events were mild or moderate and were largely consistent with the myeloablative procedure and underlying disease.

• The findings provide early human evidence for a gene therapy approach targeting the underlying genetic defect in cystinosis.

Why It Matters for Kidney Patients:

• Marks an important transition from preclinical kidney gene therapy to clinical testing in patients.

• Could eventually offer a disease-modifying approach for inherited kidney disorders rather than relying solely on lifelong management of symptoms and complications.

• Demonstrates the growing potential of gene and cell therapies in nephrology, although larger studies are needed to establish long-term safety and efficacy.

Conclusion: Advancing the Future of Kidney Disease Treatment

These seven breakthroughs demonstrate how rapidly kidney disease treatment is evolving. New targeted therapies are expanding options for patients with rare kidney diseases, while GLP-1 therapies are changing CKD management. At the same time, advances in transplantation, xenotransplantation, CAR-T therapy, and gene therapy are pushing approaches once considered experimental closer to clinical reality.

Not every breakthrough is at the same stage. Some treatments are already FDA-approved, while others have been tested in only a small number of patients and require further clinical investigation. Together, however, they reflect a broader shift toward more targeted, personalized, and disease-specific approaches to kidney care.

For clinical research, this evolution also brings new challenges. Increasingly complex trials require specialized investigators, precise patient identification, biomarker and genetic testing, long-term safety monitoring, and access to small and geographically dispersed patient populations.

At Cromos Pharma, we support nephrology clinical development across these increasingly complex research environments, helping sponsors navigate study feasibility, patient recruitment, site selection, and clinical trial execution.

If your company is developing a new therapy for kidney disease, contact us at inquiry@cromospharma.com to discuss how we can support your clinical development program.

Cromos Pharma proudly supports the Right2hope nonprofit platform, empowering patients to explore treatment options beyond traditional clinical trials. Through an intuitive, AI-supported matching algorithm, Right2hope connects patients with the most relevant expanded access, compassionate use, and right-to-try programs.